Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of ACT-293987 in Patients With Pulmonary Arterial Hypertension
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 29 Aug 2018
Price : $35 *
At a glance
- Drugs Selexipag (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Sponsors Actelion Pharmaceuticals
- 29 Aug 2018 Results (n=953) assessing safety and efficacy from GRIPHON double-blind (DB) study and its open-label extension (OLE) presented at the ESC Congress 2018: Annual Congress of the European Society of Cardiology
- 29 Apr 2016 Planned End Date changed from 1 Feb 2018 to 1 Feb 2021.
- 29 Apr 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Feb 2021.